Anne Ward Net Worth

Anne Ward biography

Anne Sempowski Ward serves as Independent Director of the Company. Ms. Ward currently serves as the Chief Executive Officer and Board Member at CURiO Brands, a consumer goods company that manufactures and sells personal care and home fragrance products. Prior to CURiO Brands, Ms. Ward served as the CEO of The Thymes, LLC from April 2012 until January 2016 when it merged with DPM Fragrance to become CURiO Brands. In July 2008, Ms. Ward co-founded The FORWARD Group, a consulting firm focused on growth strategies for mid-sized companies and key executives, and served as its Chief Executive Officer until April 2012. Previously, from October 2007 until July 2010, Ms. Ward was with Johnson Publishing Company, serving as the President and Chief Operating Officer of its Ebony, Jet and Fashion Fair Cosmetics business units. Prior to that, Ms. Ward served as an Assistant Vice President for The Coca-Cola Company from September 2006 until September 2007 and held various positions with Procter & Gamble between May 1994 and August 2006, most recently as Associate Marketing Director, Beauty. Ms. Ward holds a B.S. in Mechanical Engineering and Material Science from Duke University and an M.B.A. from Duke University’s Fuqua School of Business.

What is the salary of Anne Ward?

As the Independent Director of Vanda Pharmaceuticals Inc, the total compensation of Anne Ward at Vanda Pharmaceuticals Inc is $270,450. There are 9 executives at Vanda Pharmaceuticals Inc getting paid more, with Mihael Polymeropoulos having the highest compensation of $4,278,140.

How old is Anne Ward?

Anne Ward is 48, she's been the Independent Director of Vanda Pharmaceuticals Inc since 2019. There are 9 older and 6 younger executives at Vanda Pharmaceuticals Inc. The oldest executive at Vanda Pharmaceuticals Inc is Richard Dugan, 78, who is the Independent Director.

What's Anne Ward's mailing address?

Anne's mailing address filed with the SEC is C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON, DC, 20037.

Insiders trading at Vanda Pharmaceuticals Inc

Over the last 18 years, insiders at Vanda Pharmaceuticals Inc have traded over $267,060,716 worth of Vanda Pharmaceuticals Inc stock and bought 5,567,934 units worth $25,606,507 . The most active insiders traders include Kevin Ctang Capital Managem..., Nicole Vitullo и Jesse I Treu. On average, Vanda Pharmaceuticals Inc executives and independent directors trade stock every 31 days with the average trade being worth of $546,607. The most recent stock trade was executed by Kevin Patrick Moran on 29 July 2024, trading 2,251 units of VNDA stock currently worth $13,326.

What does Vanda Pharmaceuticals Inc do?

vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to address high unmet medical needs and improve the lives of patients.

Vanda Pharmaceuticals Inc executives and stock owners

Vanda Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Mihael Polymeropoulos,
  President, Chief Executive Officer, Director
• Timothy Williams,
  Senior Vice President, General Counsel, Secretary
• Gunther Birznieks,
  Senior Vice President - Business Development
• Dr. Mihael H. Polymeropoulos M.D.,
  Founder, Pres, CEO & Chairman of The Board
• Dr. Mihael H. Polymeropoulos,
  Founder, Pres, CEO & Director
• Joakim Wijkstrom,
  Sr. VP & Chief Marketing Officer
• Kevin Patrick Moran,
  Sr. VP, CFO & Treasurer
• Timothy Williams,
  Sr. VP, Gen. Counsel & Sec.
• Phaedra Chrousos,
  Independent Director
• Anne Ward,
  Independent Director
• H. Thomas Watkins,
  Independent Chairman of the Board
• Richard Dugan,
  Independent Director
• Stephen Mitchell,
  Independent Director
• Aranthan Jones,
  Chief Corporate Affairs and Communications Officer
• Joakim Wijkstrom,
  Senior Vice President, Chief Marketing Officer
• Kevin Moran,
  Acting Chief Financial Officer, Vice President, Treasurer
• Elizabeth Van Every,
  Head of Corp. Affairs
• Scott L. Howell,
  Chief People Officer
• Kenneth Bate,
  Director
• Michael F Cola,
  Director
• James E Deerfield Mgmt L.P....,
  
• Paolo Baroldi,
  Chief Medical Officer
• Vincent Milano,
  Director
• Steven A Shallcross,
  Sr. VP, CFO, Treasurer
• Albert W. Gianchetti,
  Sr.VP,Chief Commercial Officer
• Tage Honore,
  
• Richard L. Gulino,
  SVP & General Counsel
• James Patrick Kelly,
  EVP & Chief Financial Officer
• Gian Piero Reverberi,
  SVP & Chief Commercial Officer
• James B Tananbaum,
  Director
• Capital Ii Llccare Capital ...,
  
• Robert J More,
  10% owner
• Nicole Vitullo,
  10% owner
• Management Co Ii Llcprospec...,
  
• Brian H Dovey,
  10% owner
• Deepak Shripad Phadke,
  Vice President Manufacturing
• Ventures Iv Lprho Ventures ...,
  
• James C Blair,
  10% owner
• Inc /De Medimmune,
  10% owner
• Wayne T Hockmeyer,
  Director
• Ventures Iv Lprho Managemen...,
  
• Vi Associates, L.P. Dp,
  10% owner
• Partners Vi, L.P. Domain,
  10% owner
• Venture Partners Ii Lpprosp...,
  
• Jesse I Treu,
  10% owner
• Sciences Investment Fund Pt...,
  
• Kathleen K Schoemaker,
  10% owner
• Thomas Edward Gibbs,
  SVP, Chief Commercial Officer
• James E Deerfield Mgmt L.P....,
  
• Howard H Pien,
  Director
• Steven K Galson,
  Director
• Robert Repella,
  SVP & Chief Commercial Officer
• Stephanie Rast Irish,
  Sr. VP, Acting CFO/Treasurer
• John Joseph Feeney,
  Acting Chief Medical Officer
• Argeris N Karabelas,
  Chairman of the Board
• Brian K Halak,
  Director
• William D Clark,
  Sr VP, Chief Business Officer
• David Russ Ramsay,
  Director
• Kevin Ctang Capital Managem...,